Clinical Trials
43 trialsFASCINATE-N
Fudan University
preEMBER
Eli Lilly and Company
CARABELA
Spanish Breast Cancer Research Group
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
PETREMAC
Haukeland University Hospital
BYLieve
Novartis
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
EVANGELINE
Atossa Therapeutics, Inc.
AMALEE
Novartis
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
FACILE
Fondazione Sandro Pitigliani
RIGHT Choice
Novartis
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
NEOLETRIB
University Hospital, Akershus
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
TP-II
Palleos Healthcare GmbH
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Spanish Breast Cancer Research Group
BOOSTER
Japan Breast Cancer Research Group
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NSABP Foundation Inc
PALTAN
Washington University School of Medicine
PREDIX LumB
Karolinska University Hospital
FATIMA
Africa Middle East Cancer Intergroup
PREDIX LumA
Karolinska University Hospital
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Stanford University
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
FLAG
Samsung Medical Center
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
NYU Langone Health
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
MIRACLE
ChineseAMS
PROOF
Hospital Affiliated to Military Medical Science, Beijing
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
University of Washington
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
SWOG Cancer Research Network
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC
National Cancer Center, Korea
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
AstraZeneca
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
AstraZeneca
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)
GBG Forschungs GmbH
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
AstraZeneca